Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
A phase 1/2 trial of Pembrolizumab, Cetuximab, Afatinib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Overview
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 is a phase 1/2 interventional study registered as NCT03785249 by Mirati Therapeutics Inc., with 731 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2026-06-23. Interventions recorded: MRTX849, Pembrolizumab, Cetuximab, Afatinib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Shares Cetuximab, Bristol Myers Squibb, Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Shares Cetuximab, Bristol Myers Squibb.
- TrialA Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Shares Cetuximab, Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialPhII ICb With/Without Erbitux in MBC Pts
Shares Cetuximab, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Shares Cetuximab, Pembrolizumab, Metastatic cancer (cancer that has spread).
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Bristol Myers Squibb, Pembrolizumab.